This study investigated, through cohort analysis, whether HLA-DRB1 and -DQB1 variability is related to human papillomavirus (HPV) infection prevalence and persistence. HLA-DRB1 and -DQB1 genes were typed in 620 samples from the Ludwig-McGill cohort. HPV positivity was tested in specimens collected every 4 months during the first year of follow-up. Persistent and long-term infections were defined as at least 2 or 3 consecutive positive results for the same HPV type, respectively. The magnitudes of associations were estimated by unconditional logistic regression analysis adjusted for potential confounders. The DRB1*0301-DQB1*0201 haplotype was associated with a 2-fold reduction in risk for transient and persistent HPV infections. DRB1*1102-DQB1*0301 showed a lower-risk effect only for persistence. DRB1*1601-DQB1*0502 and DRB1*0807-DQB1*0402 were associated with a 7-fold and a 3-fold increase, respectively, in risk for persistence. The results suggest that HLA class II polymorphisms are involved in clearance and maintenance of HPV infection.
Squamous cell carcinoma of the cervix (SCCC) is an important cause of mortality among women in developing countries. Infection with oncogenic types of human papillomavirus (HPV) is considered the major risk factor for the development of malignancies in the uterine cervix [1] . However, in addition to HPV infection, other factors contribute to the carcinogenic process. A hereditary component for SCCC has been reported, and several studies indicate that genetic background of the host is important for SCCC susceptibility [2] [3] [4] .
Part of the genetic susceptibility to SCCC has been attributed to polymorphisms in major histocompatibility complex (MHC) genes [4] . These genes encode for the cell-surface human leukocyte antigen (HLA) class I (HLA-A, -B, and -C) and class II (HLA-DR, -DQ, and -DP) molecules, which play an important role in the regulation of the immune system. Most nucleated cells express HLA class I genes, whereas expression of HLA class II genes is restricted to specialized antigen-presenting cells. HLA class I and class II molecules present antigenic peptides to CD8 and CD4 T cells, respectively. The variability observed among these molecules is located in the peptide-binding region, which is important in determining the antigen repertoire that is displayed to T cells by each HLA molecule. The interaction between the HLA-peptide complex and the T cell receptor is an essential and specific step in T cell activation [5] .
With regard to HLA polymorphisms and the risk of SCCC, discordant results have been observed among different populations or even in the same population. Higher risks for SCCC have been described in association with several HLA alleles, predominantly the DQB1*03 alleles [4, 6] and the DRB1*1501-DQB1*0602 haplotype [7] [8] [9] . In some reports, the associations were stronger or specific to tumors containing a particular HPV type [7, 8] . However, several reports did not find associations with DQB1*03 alleles [7] [8] [9] [10] , and an inverse association has been described for the DRB1*1501-DQB1*0602 haplotype [10] . Few HLA alleles or haplotypes are regularly associated with a lower risk for SCCC. Several studies conducted in different populations described a lower risk for SCCC in association with the DRB1*01 and DRB1*13 alleles or haplotypes [6] [7] [8] [9] [10] [11] .
Although the prevalence of HPV infection is 15%-40% among sexually active women, most of these infections are cleared within a short time [12] . A higher risk for the development of squamous intraepithelial lesions (SILs) and SCCC is associated with persistent infection with oncogenic HPVs [13] [14] [15] . Animal models have demonstrated that domestic rabbits differ in their ability to clear a papillomavirus infection over time, depending on their MHC haplotypes [16] . To date, similar investigations have not been conducted for humans, because only relatively recently were cohort studies with repeated measurements of HPV exposure and assessment of cervical malignant lesions initiated. To investigate the association pattern between HLA class II genes and the natural history of HPV infections, we analyzed polymorphisms of HLA-DRB1 and -DQB1 genes in samples from the Ludwig-McGill cohort.
Methods
Study population. The Ludwig-McGill Cohort Study is an ongoing investigation of the natural history of HPV infection and the risk of cervical neoplasia. The methodology used for subject recruitment, scheduled returns, epidemiologic data, medical procedures, and biological sampling has been described elsewhere [17] . In brief, 2528 women with permanent residence in the city of São Paulo, Brazil, were enrolled in the study between 1993 and 1997. These women attended a comprehensive maternal and child health program catering to low-income families. Study subjects were 18-60 years old and were followed over 5 years. In the first year, besides the enrollment visit, a new visit was prescheduled every 4 months. At each visit, ectocervical and endocervical cell specimens were collected for cytologic and HPV DNA analyses. The remaining cervical cells were kept refrigerated in buffer at 4ЊC at the clinic for at most 5 days and then were kept frozen at Ϫ20ЊC at the São Paulo branch of the Ludwig Institute for Cancer Research until testing.
HPV typing. HPV detection and typing were done by polymerase chain reaction (PCR)-based methods, as described elsewhere [18] . A 450-bp fragment of the viral L1 gene was amplified with the consensus primers MY09 and MY11. The PCR products were dot blotted onto nylon membranes and hybridized with specific 32 P-labeled probes that discriminate among most genital HPV types. Ambiguous results were resolved by using restriction fragment-length polymorphism analysis of the L1-amplified fragment with a set of restriction enzymes [19] . Each PCR reaction included negative and positive controls. Amplification of a 268-bp fragment of the b-globin gene was used to assess DNA quality.
HLA typing. We attempted HLA typing for 651 women from the Ludwig-McGill cohort, corresponding to those first enrolled in the study and for whom we had completed HPV typing for the first 4 visits (first year of follow-up). Thirty-one samples were excluded because DNA was not available for amplification.
High-resolution typing for HLA-DRB1 and -DQB1 genes was done, by PCR-based methods, for 620 samples. We typed both HLA-DRB1 and -DQB1 genes in 604 samples. Amplification for HLA-DRB1 and -DQB1 failed in 7 and 9 samples, respectively. The protocols, primers, and probes for PCR and hybridization reactions used in this study followed recommendations of the 12th International Histocompatibility Workshop and Conference [9, 20] . In brief, we amplified the polymorphic second exon of the HLA-DRB1 and -DQB1 genes. Amplification was assessed by electrophoresis on 1.5% agarose gels stained with ethidium bromide and visualized under UV light. Dot-blotted PCR products were hybridized with sequence-specific 3 biotin-labeled oligonucleotide probes, to discriminate among HLA alleles. After incubation with a streptavidin-peroxidase conjugate, the hybridized probes were detected by chemiluminescence with the ECL kit (Amersham Pharmacia Biotech).
When required, the high-resolution typing results were translated into groups of alleles that resemble the detection spectrum of HLA serology (e.g., DRB1*1501, *1502, and *1503 alleles were grouped as DRB1*15). HLA haplotypes were inferred from known linkagedisequilibrium patterns between HLA-DRB1 and -DQB1 alleles in the Brazilian population [21] .
Statistical analysis. The magnitude of association between the HLA markers and the occurrence and persistence of HPV infection were measured by the odds ratio (OR) and respective 95% confidence interval (CI). Crude and adjusted ORs were estimated, by unconditional logistic regression, using SPSS statistical software (version 10.0). Age and ethnicity were considered potential confounders and were adjusted for a priori. Age was divided into 4 categories (18-24, 25- [18] .
The category of cumulative HPV positivity was composed of women who were positive for HPV DNA at least once in the first year of follow-up. Persistent and long-term infections were defined as 2 and 3 consecutive positive results for the same HPV type, respectively, whereas transient infections were defined as a single positive result for a particular HPV type. The reference group for comparison was women who were consistently negative for HPV during the first year of follow-up.
To estimate the effect of each allele, comparison was made between subjects positive and those negative for a particular allele. For haplotypes, comparison was made between subjects with neither of the alleles that comprise the specific haplotype and subjects carrying that haplotype. Generalized estimating equations (GEEs) were used to estimate the OR and 95% CI for persistence of a particular HPV infection to the next visit, with respect to the results of the previous visit. This method allows for multiple events of persistence while adjusting the regression-model estimates for the correlated nature of repeated outcomes observed for subjects. We used Stata software (version 6; StataCorp) for statistical analyses of GEEs.
The number of associations expected by chance was estimated by using a random database generated from the original data set used in the analysis. The data were divided into 2 blocks of information that maintained the dependence among several variables. The first block was composed of information on HLA type, age, and ethnicity and the second included data for the outcome variables. In the next step we randomly mixed the 2 blocks of information. The result was a database that preserved information on related variables, although the outcomes were randomly distributed among samples. We repeated all the analyses by using this random database and counted the number of associations statistically significant at the 5% level. 
Results
Sociodemographic characteristics. The mean age was 32.5 and 31 years for women who were HPV negative and those who were HPV positive, respectively, in the first year of followup. The highest rate of cumulative HPV positivity was among women 18-24 years old: 56% had у1 positive result for HPV in the first year of follow-up. Ethnicity was noted for 619 of the 620 women for whom HLA typing was done. Most women were classified as white (65.6%), and 45.6% were HPV positive. Nonwhite women had a higher prevalence of HPV positivity (53.5%). Although a majority (60.3%) of the cohort had had a minimum level of elementary school education, a slightly higher proportion (55.3%) of women with a high school or college education were HPV positive at least once.
HPV positivity. Tables 1-3 show the age-and ethnicityadjusted associations between cumulative HPV positivity and typing results for the HLA-DQB1 (table 1) and HLA-DRB1 (table 2) alleles and for their corresponding haplotypes (table  3) . The outcomes investigated were cumulative positivity for any HPV type, only nononcogenic HPV, oncogenic HPV, and HPV-16. Women negative for HPV at all visits in the first year formed the control group for all comparisons. Consistent inverse associations were found for the DQB1*0201 (OR, 0.64; 95% CI, 0.5-0.9) and DRB1*0301 (OR, 0.46; 95% CI, 0.3-0.7) alleles and the DRB1*0301-DQB1*0201 (OR, 0.45; 95% CI, 0.3-0.7) haplotype. The magnitude of the ORs was similar for nononcogenic and oncogenic HPVs and for HPV-16. Inverse associations, albeit less consistent across HPV outcomes, were also found for the DRB1*1102 allele (OR, 0.37; 95% CI, 0.2-0.9) and the DRB1*1102-DQB1*0301 haplotype (OR, 0.41; 95% CI, 0.2-1.0), with a stronger inverse association with HPV positivity for oncogenic types (OR, 0.24, and 95% CI, 0.1-0.8, for the allele; OR, 0.26, and 95% CI, 0.1-0.9, for haplotype; tables 2 and 3).
Positive associations with cumulative positivity for any HPV type were found for the DQB1*0502 (OR, 2.10; 95% CI, 1.0-4.3) and DRB1*1601 (OR, 3.99; 95% CI, 1.3-12.7) alleles and for the DRB1*1601-DQB1*0502 haplotype (OR, 5.27; 95% CI, 1.5-19.1) (tables 1-3). The latter associations were weaker for oncogenic HPVs and HPV-16 positivity. Among the DQB1*0303 carriers, none of the HPV-positive samples were exclusively positive for nononcogenic types ( , Fisher's P p .009 exact test; table 1). We also observed a slight increase in the risk for oncogenic HPV positivity among DQB1*0602 carriers (OR, 1.49; 95% CI, 1.0-2.3). The DRB1*0807 (OR, 6.11; 95% CI, 1.7-21.3) and DQB1*0402 (OR, 1.94; 95% CI, 1.0-4.0) alleles and the DRB1*0807-DQB1*0402 (OR, 6.36; 95% CI, 1.8-22.4), DRB1*0302-DQB1*0402 (OR, 2.52; 95% CI, 1.0-6.6), and DRB1*1302-DQB1*0604 (OR, 3.18; 95% CI, 1.1-9.1) haplotypes were associated with a higher risk for HPV-16 positivity (tables 1-3). On the other hand, the nonwhite DRB1*1302-DQB1*0501 haplotype was positively associated with nononcogenic HPV positivity (OR, 6.48; 95% CI, 1.2-35.0; table 3).
DR4 haplotypes also showed a different behavior, depending on the linked HLA-DQB1 allele, although DR4-DQB1*0301 haplotypes were associated with a higher positivity for HPV (OR, 6.90; 95% CI, 1.5-32.2) regardless of grouping. The two DR4 alleles most frequently found in the DR4-DQB1*0301 haplotype were DRB1*0401 and DRB1*0407 (data not shown). No association with HPV positivity was found for DR4-DQB1*0302 haplotypes (OR, 0.91; 95% CI, 0.6-1.4; table 3). No significant associations were observed for any of the DR4 haplotypes (data not shown). Increased ORs for HPV outcomes were observed for the DRB1*0803 allele, but the estimates were imprecise (table 2) .
HPV transience and persistence. The associations between the HLA-DQB1 and -DRB1 polymorphisms and persistence of HPV infections are shown in tables 4-6 for the HLA-DQB1 and -DRB1 alleles and their corresponding haplotypes, respectively. Transient infections were defined as a single positive result for a particular HPV type in the first year of follow-up. Two or more positive results for the same HPV type were classified as a persistent infection. We also selected samples positive for HPV that were obtained over at least 3 visits, to measure the effects on long-term persistence. The probability of persistence of HPV to a next visit, given a positive result for the same HPV type in the previous visit, was also evaluated. DQB1*0201, DRB1*0301, and the DRB1*0301-DQB1*0201 haplotype carriers were found in a smaller proportion of women with either transient or persistent HPV infection, compared with HPV-negative women (tables 4-6).
An inverse association between DRB1*1102 (OR, 0.10; 95% CI, 0.0-0.8) and the haplotype DRB1*1102-DQB1*0301 (OR, 0.11; 95% CI, 0.0-0.8) and persistence for at least 2 visits was observed. A lower risk for long-term persistence was found for the DQB1*0501 (OR, 0.38; 95% CI, 0.2-0.8) and DRB1*01 (OR, 0.32; 95% CI, 0.1-0.8) alleles and the DRB1*01-DQB1*0501 haplotype (OR, 0.33; 95% CI, 0.1-0.9) (tables 4-6). Both the DRB1*0101 and DRB1*0102 alleles were found in a smaller proportion of women with long-term persistence, although the deviations were not statistically significant (data not shown).
A higher risk for long-term persistent infections was observed for the DQB1*0502, DRB1*04, DRB1*0807, DRB1*1401, and DRB1*1601 alleles, with ORs of 1.86-9.30 (tables 4 and 5). In addition, the DRB1*0807-DQB1*0402 and DRB1*1601-DQB1*0502 haplotypes also were associated with a moderateto-high likelihood of having a persistent HPV infection (table   6 ). However, the association between DRB1*1601-DQB1*0502 haplotype and persistence to the next visit was not strong (OR, 1.57; 95% CI, 0.8-3.3).
On the other hand, the DQB1*0601 and DRB1*0403 alleles and the DRB1*0403-DQB1*0302 haplotype were associated with a higher risk for persistence of the same HPV type at the next visit with ORs of 3-9 (tables 4-6). The DRB1*0403-DQB1*0302 haplotype and the DQB1*0601 allele, which were found predominantly among white women, were not present in samples transiently infected by HPV. The DRB1*04-DQB1*0301 haplotype was found in a higher proportion of women with transient infections, compared with HPV-negative samples, but showed no significant association with persistence. The opposite was observed for DRB1*04-DQB1*0302 haplotypesmainly, DRB1*0401-DQB1*0302, DRB1*0403-DQB1*0302, and DRB1*0404-DQB1*0302-which showed positive associations with persistence over time (table 6) .
We also analyzed the data stratified by ethnicity, retaining the adjustment for age. After stratification, statistical significance was lost for most associations, because of the small numbers in each class. The direction and strength of the associations were maintained in both ethnic groups for the haplotypes DRB1*01-DQB1*0501, DR4-DQ3, DRB1*0807-DQB1*0402, DRB1*1102-DQB1*0301, and DRB1*1302-DQB1*0501 (data not shown). The associations observed with the DRB1*1401 allele and the DRB1*0301-DQB1*0201 and DRB1*1302-DQB1*0604 haplotypes were stronger in the nonwhite than in the white group, although the trends were similar in both groups (data not shown). For the DRB1*1601-DQB1*0502 haplotype, the stratified analysis was impaired by the unequal distribution of this haplotype between the HPV-negative and -positive groups, depending on ethnicity. The DRB1*1601-DQB1*0502 haplotype was found in 15 women: 12 were classified as white, and all were HPV positive. In contrast, all of the DRB1*1601-DQB1*0502-positive samples from nonwhite women were HPV negative. We also estimated the number of significant associations expected by chance in these analyses. Considering the variables that describe HPV positivity, no random associations were found for HLA-DQB1 alleles, at a significance level of 5%, whereas 6 and 3 random associations were observed for HLA-DRB1 alleles and the DRB1-DQB1 haplotypes, respectively. These numbers were considerably smaller than the number of significant associations observed in our study analyses. The number of random associations obtained for variables related to HPV transience and persistence were 4 and 2 for the HLA-DRB1 alleles and the DRB1-DQB1 haplotypes, respectively.
Discussion
Previous case-control studies have reported a role for HLA polymorphisms in susceptibility to cervical cancer and HPV infection [4, [6] [7] [8] [9] [10] [11] . However, in these studies, the effect of these polymorphisms on HPV persistence could not be evaluated because the studies were based on single measurements of HPV exposure. In the present report, we analyzed the polymorphisms in HLA class II genes (HLA-DQB1 and -DRB1) in a longitudinal study of the natural history of HPV infections. This investigation is based on repeated measures of HPV status obtained during the first year of follow-up. We were able to identify several HLA class II alleles and haplotypes that were associated with risk for cumulative HPV positivity and persistence.
Although a cohort study approach has several advantages over case-control studies, it also has some limitations. Specifically, we equated the presence of a persistent infection with the occurrence of 2 consecutive visits with positive tests for the same HPV type, determined by consensus PCR protocol. Fluctuations in virus load below the detection threshold of PCR may have caused some cases of persistent infection to be misclassified as transient. However, since HPV typing was done without any knowledge of HLA polymorphism results, the effect of such misclassification would have been to reduce the observed associations toward the null. Also reassuring is the fact that, in a previous study that used results from HPV variant sequencing, PCR typing alone was sufficient for defining persistent infections [22] .
We found that women harboring the DRB1*1601 and DQB1*0502 alleles or the DRB1*1601-DQB1*0502 haplotype had a higher risk of HPV positivity and long-term persistence over the first year of follow-up. However, the effect of DRB1*1601-DQB1*0502 on cumulative HPV positivity was stronger for nononcogenic HPVs in our sample and practically absent for HPV-16. In this case, despite the higher susceptibility for HPV infection and persistence, the overall effect on cervical cancer risk might not be important. We know of no previous reports showing an association between DRB1*1601-DQB1*0502 and cervical cancer. Unfortunately, we could not investigate the role of HLA polymorphisms in risk for SILs in this cohort because our study has yet to accrue sufficient lesion outcomes to reach the required statistical power needed for this analysis.
We cannot refute the possibility that the DRB1*1601-DQB1*0502 haplotype and other associations are spurious, because of the large number of comparisons made in our study. On the other hand, we did not find an association between the DRB1*15 alleles or haplotypes and a higher risk for cumulative HPV positivity or persistence, although a higher risk for SCCC was previously described for DRB1*15 alleles in Brazilian [9] and other populations [7, 8] . Recently, in a case-control study with multiple measurements of HPV infection in cervical smears, Beskow et al. [23] described a higher risk of cervical carcinoma in situ and long-term HPV infection associated with the DRB1*1501-DQB1*0602 haplotype. However, the interval between measurements of HPV exposure and the follow-up period was longer than in our study. Furthermore, cases were selected on the basis of disease status, whereas we followed healthy women in our cohort study.
An interaction between the HLA-DRB1 and -DQB1 alleles is suggested by the results observed for the DRB1*04 and DRB1*13 haplotypes. The presence of the DQB1*0301 allele in DR4 haplotypes was associated with a higher positivity for HPV but not with persistence. However, opposite associations were observed for DRB1*04-DQB1*0302 haplotypes and HPV positivity or persistence, compared with the DR4-DQB1*0301 haplotype. No significant associations were verified individually for the DRB1*04 and DQB1*03 alleles, except for DRB1*0403 and persistence of HPV at next visit. There is no evidence from previous studies to support an interaction between DR4 and DQ3 with regard to risk for cervical cancer. These results need to be evaluated further in our cohort by increasing the number of HLA-typed samples. Previous case-control studies found that the presence of some DRB1*04 alleles, as well as DQB1*0301 and DQB1*0302, are risk factors for cervical cancer in some populations. DRB1*0405 and DRB1*0407 conferred a higher risk for cervical cancer in Hispanic populations [7] , whereas DRB1*0401 was a risk factor in British populations [6, 24] . We observed a consistent association between long-term persistence and the DRB1*0401 allele and DRB1*0401-DQB1*0302 haplotype. For DRB1*13 haplotypes, we observed that DRB1*1302-DQB1*0604 was positively associated with HPV-16 presence, although most of these infections were transient. The DRB1*1302-DQB1*0501 haplotype was also found in a higher proportion of transient infections, although in these samples only nononcogenic HPVs were detected.
Analysis of HPV infection by oncogenicity and by persistence for specific HPVs can be informative because distinct HPVs may have diverse oncogenic potentials and tendencies to persist. Furthermore, epitopes derived from a particular HPV type have different antigenic properties, depending on the immunogenetic background of the host. Interactions among the HLA molecule, the antigenic peptide, and the T cell receptor are highly specific and essential in the T cell activation process [25] .
We analyzed the association between HLA class II polymorphisms and the cumulative positivity for HPV-16, the most frequent HPV type in this cohort. Persistence could not be evaluated for particular HPV types or for oncogenic groups because of the limited number of samples. The DRB1*0807 allele and DRB1*0807-DQB1*0402 haplotype were associated with a 6-fold and a 4-fold increase in risk for cumulative HPV-16 positivity and long-term persistence, respectively. The DRB1*0807 allele is found only in South American populations, mainly in Brazil, where this allele is identified with high frequency in some Amerindian populations. In the Ticuna, a native South American population, the frequency of the DRB1*0807 allele is 22.5% [26] . In such populations, depending on the strength of the association, the higher susceptibility for HPV-16 infection and persistence could be linked to an increased risk for cervical cancer. However, we do not have information about the incidence of cervical cancer in this native Brazilian population. We also observed a higher risk for persistence of HPV infections associated with the DQB1*0601 allele, which was found in samples carrying persistent infections for HPV-31 and HPV-58. In a previous case-control study with Brazilian patients [9] , the DQB1*0601 allele was found in 5 of 161 case patients with invasive SCCC but in none of the 257 control subjects. Furthermore, of the 5 tumors, 4 were positive for HPV-16, HPV-31, HPV-33, or HPV-58, which are phylogenetically related [27] . Although uncommon in the Brazilian population, the DQB1*0601 allele is the most frequent DQ6 allele in Asian populations [28] . However, little information is available concerning HLA class II variability and risk of cervical cancer in these populations.
We did not observe strong parallelism between the identified HLA class II-related risks of HPV persistence and those previously detected for invasive cervical cancer in Brazil (data not shown). However, HLA susceptibility to invasive cervical cancer was described in a population living in northeast Brazil [9] , whereas women of the Ludwig-McGill cohort live in the southeast [17] . Unfortunately, there are no reports of HLA variability among patients with cervical cancer in southeastern Brazilian populations. The frequency of some HLA-DRB1 and -DQB1 alleles varies according to the population analyzed. Although we adjusted our data for ethnicity, we cannot exclude the possibility that some residual confounding may have remained because of misclassification. Although there were few nonwhite women, we found little difference in risks between ethnic groups.
Several genetic loci must contribute to the genetic susceptibility to HPV persistence and cervical cancer, including the HLA genes located in the MHC region. Codominance is a characteristic of HLA genes, and it is plausible that the risk for HPV persistence attributable to these genes is an average of the effect of both alleles at each HLA locus, in addition to an overall effect produced by the interaction among alleles in different HLA genes. We could not evaluate the joint effects of HLA-DRB1 and -DQB1 alleles and haplotypes, because of the insufficient number of HLA-typed samples. Furthermore, other genes located in the MHC region and closely linked to HLA genes may also participate in the genetic susceptibility to HPV infection and cervical cancer. Analysis of the variability of tumor necrosis factor (TNF)-a microsatellites revealed that the TNF-a11 and HLA-DQ6 alleles have a synergistic effect on the risk for SILs [29] . Polymorphisms in HLA class I genesmainly, with regard to HLA-B7 specificity-are also associated with genetic susceptibility to cervical cancer [10] and a poorer outcome [30] . An extended analysis of the MHC region will allow us to explain some of the discrepancies observed regarding HLA-related susceptibility among individuals.
On the other hand, we found an inverse association between long-term HPV persistence and the DRB1*01-DQB1*0501 and DRB1*1102-DQB1*0301 haplotypes. A similar associ- NOTE. Table 6 is published in its entirety in the electronic edition of the Journal (http://www.journals.uchicago.edu/JID/); a portion is shown here to indicate the table's form and content. ORs and 95% CIs, adjusted for age and ethnicity, were estimated by unconditional logistic regression, contrasting transience and persistence against data for HPV-negative women, except when analyzing persistence to next visit. ND, not defined.
a Defined as at most 1 visit positive for a given HPV type. b Defined as у2 visits positive for the same HPV type. c Defined as у3 visits positive for the same HPV type. d ORs and 95% CIs, adjusted by age and ethnicity, were estimated by generalized estimating equation analysis, taking into account consecutive pairs of visits (ϩ/ϩ vs. ϩ/Ϫ).
ation was found for DRB1*1301, although it was not statistically significant. We previously reported that DQB1*05, DRB1*0101, and DRB1*1302 conferred a lower risk for invasive SCCC in a Brazilian population [9] . Furthermore, the DRB1*01 and DRB1*13 alleles are protective against cervical cancer in other populations [6] [7] [8] [9] [10] [11] 23] . This protective effect could result from a proper presentation of an HPV epitope by a particular HLA allele, leading to a more effective immune response against HPV. Since clearance of HPV infection may be essential in avoiding the development and progression of cervical cancer, this could explain the agreement of several studies concerning HLA-protective effects for HPV infection and cervical cancer. In the present study, the DRB1*0301-DQB1*0201 haplotype, although associated with a lower risk for HPV positivity, did not influence the persistence of HPV infections. In Brazilian patients, no association was found between the DRB1*0301-DQB1*0201 haplotype and risk of invasive SCCC [9] . Future studies that take into account the potential modifiers of HPV natural history may help to clarify the role of HLA polymorphisms as risk factors for HPV persistence and cervical cancer. As our HLA-typed cohort increases in size and as follow-up is extended, we expect to obtain the requisite statistical power for many of these analyses. However, these initial findings demonstrate that HLA polymorphisms have a role in the natural history of HPV infections. The detection of slight differences among subjects in response to particular HPV antigens is essential to explain the HLA-associated risk for HPV infection and SCCC. Understanding the relation between genetic susceptibility to HPV infections and cervical cancer may provide important information for the elaboration of screening and HPV vaccination programs.
